MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
22.32
+0.06
+0.27%
After Hours: 22.69 +0.37 +1.66% 19:42 04/01 EDT
OPEN
22.22
PREV CLOSE
22.26
HIGH
22.89
LOW
21.99
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
28.35
52 WEEK LOW
13.40
MARKET CAP
3.81B
P/E (TTM)
9.70
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACAD last week (0323-0327)?
Weekly Report · 2d ago
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
NASDAQ · 5d ago
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance
Simply Wall St · 6d ago
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Benzinga · 03/25 19:43
Acadia Pharma upgraded at BofA following stock pullback
Seeking Alpha · 03/25 15:51
Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
TipRanks · 03/25 13:50
ACADIA Pharmaceuticals Price Target Maintained With a $29.00/Share by B of A Securities
Dow Jones · 03/25 12:54
ACADIA Pharmaceuticals Raised to Buy From Neutral by B of A Securities
Dow Jones · 03/25 12:54
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.